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Skeletal muscleAmyotrophic lateral sclerosis (ALS) is a severe and fatal neurodegenerative disease of still unknown pathogene-
sis. Recent ﬁndings suggest that the skeletal muscle may play an active pathogenetic role. To investigate ALS's
pathogenesis and to seek diagnostic markers, we analyzed skeletal muscle biopsies with the differential expres-
sion proteomic approach. We studied skeletal muscle biopsies from healthy controls (CN), sporadic ALS (sALS),
motor neuropathies (MN) and myopathies (M). Pre-eminently among several differentially expressed proteins,
Myosin binding protein H (MyBP-H) expression in ALS samples was anomalously high. MyBP-H is a component
of the thickﬁlaments of the skeletalmuscle and has strong afﬁnity formyosin, but its function is still unclear. High
MyBP-H expression level was associated with abnormal expression of Rho kinase 2 (ROCK2), LIM domain kinase
1 (LIMK1) and coﬁlin2, thatmight affect the actin–myosin interaction.Wepropose thatMyBP-H expression level
serves, as a putative biomarker in the skeletal muscle, to discriminate ALS from motor neuropathies, and that it
signals the onset of dysregulation in actin–myosin interaction; this in turn might contribute to the pathogenesis
of ALS.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by progressive
motor neuron degeneration in the brain and spinal cord and by muscle
atrophy; collectively, these ailments lead to paralysis and death typical-
ly within three to ﬁve years of diagnosis [1–4]. Most ALSs are sporadic;
only 5–10% of cases are genetically linked, of which 20% showmutation
in the Cu/Zn superoxide dismutase SOD1 gene. More recently, other
genetic variants, including TARDBP (TAR DNA-binding protein) and
FUS (Fused in Sarcoma) mutations, along with C9orf72 (chromosome
9 open reading frame 72) repeat expansions, have been identiﬁed in
ALS patients. Although several hypotheses have been proposed as to
the pathogenesis of ALS, the persistent lack of an effective therapyCNS, central nervous system;
ization tandem mass spectrom-
blot; MyBP-H, Myosin binding
Raffaele Scientiﬁc Institute, via
ights reserved.necessitates a better understanding of the disease mechanisms. Gluta-
mate excitotoxicity, oxidative stress, mitochondrial dysfunction, neuro-
ﬁlament accumulation and other explanations have been linked to ALS,
but their precise respective roles in disease pathogenesis still need to be
determined [1–4].
Skeletal muscle has commonly been considered the ﬁnal target of
motor neuron degeneration. However, recent ﬁndings in genetically
linked ALS cases suggest that skeletal muscle is actively involved in
the pathogenesis of the disease. A transgenic mouse model expressing
mutated SOD1G93A under the transcriptional control of muscle-speciﬁc
promoter showed progressive muscle atrophy, contractile apparatus
alteration and mitochondrial dysfunction without evident signs of
motor neuron degeneration [5,6]. The result of this study challenges
the idea thatmotor neuron degeneration, which is caused by transgenic
SOD1G93A overexpression in ubiquitous transgenic animals, is the pri-
mary cause of muscle atrophy. Muscle atrophy in these animals is one
of the earliest detectable events prior to neuromuscular junction alter-
ations, retrogade axonal degeneration, andmotor neuron death [3,6–8].
To study speciﬁc modiﬁcations occurring in proteins of the skeletal
muscle at the onset of the disease inALS patients,we applied a differential
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that of healthy controls, motor neuropathies and myopathies. This ap-
proach revealed the increased expression of MyBP-H in ALS samples.
The said expression may constitute an early biomarker of ALS disease,
and shed light on the disease mechanisms.
2. Materials and methods
2.1. Patients
Following approval of the institutional ethical review board and the
granting of informed patient consent, skeletal muscle samples were
collected bymeans ofmuscle biopsy and stored in the Institute of Exper-
imental Neurology INSPE-Biobank (San Raffaele Scientiﬁc Institute,
Milan, Italy). Collection was carried out in accordance with the Declara-
tion of Helsinki. Specimens were collected according to the clinical
standard procedures, as previously described [9,10], by either gracilis
or vastus lateralis muscle biopsy from patients diagnosed with motor
neuropathy or ALS or myopathies.
Samples obtained frompatientswith no pathological alterations and
no diagnosis of neuromuscular disorder were used as healthy controls.
After biopsy, a cylinder of vastus lateralis or gracilis muscle tissue
(10 mm long and 4 mm wide) was rapidly frozen by immersion in
isopentane and kept cool in liquid nitrogen.
The groups analyzed were: sporadic amyotrophic lateral sclerosis
(sALS, n = 17), motor neuropathies (MN, n = 9), myopathies
(M, n = 6) and healthy controls (CN, n = 11); Table 1 describes fea-
tures in detail. All ALS and MN patients were at their ﬁrst diagnosis
and were drug-free. Neurological diagnosis was performed in accor-
dance with standard clinical neurophysiological and neuropathological
criteria, as described in [9,11]. Exclusion criteria included: HIV or Hepa-
titis C virus positive; previous cerebral ischemic events; deepmetabolic
deﬁcit and other neurodegenerative diseases.
2.2. Sample preparation, two-dimensional electrophoresis (2DE), image
analysis, mass spectrometry (MS), SDS-PAGE and Western blot
Analysis used skeletal muscle homogenate. Muscle biopsy (100 mg
each sample) was minced, resuspended in a 2 ml rehydration solution
(urea 8 M, chaps 4% w/v) and then homogenized with DounceTable 1
Patient and control features.
CN sALS MN
Sex Age Mus Sex Age Mus Se
CN 1 F 45 v ALS 1 F 50 g MN 1 M
CN 2 F 32 v ALS 2 M 46 g MN 2 M
CN 3 F 36 v ALS 3 M 42 g MN 3 M
CN 4 M 24 v ALS 4 F 50 g MN 4 M
CN 5 F 35 v ALS 5 M 54 g MN 5 M
CN 6 M 55 v ALS 6 M 63 g MN 6 M
CN 7 M 35 v ALS 7 F 48 g MN 7 M
CN 8 F 48 v ALS 8 F 65 g MN 8 F
CN 9 F 43 v ALS 9 M 51 g MN 9 F
CN 10 F 45 v ALS 10 M 54 g
CN 11 M 60 g ALS 11 M 55 g
ALS 12 F 65 g
ALS 13 M 70 g
ALS 14 M 55 g
ALS 15 F 56 v
ALS 16 F 68 v
ALS 17 M 74 v
4M/7F 10M/7F 7
m ± sd 41.6 ± 10.5 56.8 ± 9.1
Gender: no statistical differences among groups (Fischer's exact test) except for MN vs. M (p =
Age: statistical differences (Student's t-test) have been found for CN vs. ALS (p = 0.0004), CN
CN = healthy subjects; sALS = sporadic amyotrophic lateral sclerosis; MN = motor neur
Diagn = diagnosis; m = mean; sd = standard deviation. MMNCB = multifocal moto
DM = dermatomyositis; NM = necrotizing myositis; T = toxic; MD = muscular dystrophy.equipment. After centrifugation, the supernatant was collected and
intact pieces of tissue were thus discarded. Protein concentrationwas de-
termined by the Bradford (BioRad) method, and aliquots were stored at
−80 °C. Each homogenate sample (100 μg) was resuspended in a buffer
containing urea (8 M), CHAPS (4% w/v), DTT (65 mM), 0.2% v/v IPG-
buffer 3–10 NL (GE Healthcare, Milan, Italy) and 0.05% Bromophenol
blue, and used for the generation of 2DE maps as described in [12,13].
Isoelectric focusing was performed by using either 7 or 18 cm pH 3–10
non-linear gel strips (GE-Healthcare), while second dimension was
performed on 9–16% gradient SDS-PAGE. Gels were stained with MS-
compatible silver staining, and images were acquired at high resolution
with the ProXPRESS system (Perkin Elmer). The protein resolved on
7 cm small 2DE gelswere electro-transferred to nitrocellulosemembrane
for Western blot (WB) analysis (see below). Images of 2DE proﬁles
underwent software-assisted analysis by means of Progenesis Same-
Spot (Nonlinear Dynamics), and the identiﬁed differentially expressed
protein spots (ANOVA p b 0.05, as analyzed by Progenesis Stat) were
excised from gels, reduced, alkylated, and in-gel digested overnight with
bovine trypsin (Roche Diagnostics Corp.), as previously described [14].
Five microliters of digested sample, acidiﬁed to 1% with Formic Acid,
were injected into a capillary chromatographic system (Agilent1100
Series) that was equipped with a Nano Pump (Agilent). Peptide separa-
tion occurred on a homemade RP C18 nano column. The eluting peptides
were ionized by a nanoESI on-line source and analyzed on an API QStar
PULSAR (AB-Sciex, Toronto, Canada) mass spectrometer. Full scan mass
spectra ranging from m/z 350 to 1600 were collected and, for each MS
spectrum, the two most intense doubly and triply charged ion peaks
were selected for fragmentation.MS/MS spectra dataﬁles fromeach chro-
matographic run were combined and converted to Mascot generic ﬁles
with Mascot.dll (version 2.2.07) by means of Analyst QS 1.1 (AB Sciex).
All MS/MS samples were analyzed with a MASCOT engine that searched
the UniProt_CP_human_2012_11 database. We used a peptide mass tol-
erance of 200 ppm and 0.3 Da respectively for precursor and fragment
ions. The other search parameters were: two missed cleavages allowed;
oxidation of Methionine as a variable modiﬁcation, and carbamidometh-
ylation as a ﬁxed modiﬁcation.
The validation of differential protein expression levels was under-
taken by WB analysis performed on 10 μg muscle homogenate biopsy
sample lysates, and used antibodies speciﬁc for the identiﬁed proteins,
as described in [12,13]. The antibodies used were: anti-MyBP-H,M
x Age Mus Diagn Sex Age Mus Diagn
39 g MMNCB [c] M 1 F 37 v DM [a/c]
57 g MMNCB [c] M 2 F 58 v NM [a/c]
57 g MMNCB [c] M 3 F 31 v T [a]
65 g MMN [c] M 4 F 31 v T [a]
60 g MN [c] M 5 F 52 v MD [c]
60 g MN [sa] M 6 M 27 v MD [c]
76 g MN [c]
45 g MN [a]
47 g MN [c]
M/2F 1M/5F
56.2 ± 11.2 39.3 ± 12.7
0.0406).
vs. MN (p = 0.0077), ALS vs. M (p = 0.0015), and MN vs. M (p = 0.0177).
opathies; M = myopathies. Mus = muscle; v = vastus muscle; g = gracilis muscle;
r neuropathy with conduction blocks; MMN = multifocal motor neuropathy.
[c] = chronic; [sa] = subacute; [a] = acute.
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myosin, -neuropolypeptide H3 (all from Abcam), and -myosin light
chain (Cell Signaling). WB analysis was also performed to investigate
the expression of proteins hypothetically related to MyBP-H's function.
The antibodies used were: anti-myosin binding protein-C (MyBP-C),
-thyroid transcription factor 1 (TTF1), -coﬁlin2 (from Abcam), -LIM
domain kinase 1 (LIMK1), and -Rho kinase 2 (ROCK2) (from Cell
Signaling). Secondary HRP-conjugated antibodies were from Dako.
Antibody reactivity was quantiﬁed by densitometric analysis (Molecular
Dynamics Personal SI Laser Densitometer) and normalized by total pro-
tein loading and actin expression, as in [15].
2.3. Immunoprecipitation
Homogenate lysate proteins (100 μg) were subjected to immuno-
precipitation with 1 μg of either monoclonal antibody anti-MyBP-H
(Abcam 55561) or the rabbit polyclonal serum anti-MyBP-H (Abcam
98187) coupled to protein G-Sepharose (GE-Healthcare). Immunopre-
cipitates were washed and bound proteins were eluted by incubation
of the beads for 4 min at 99 °C together with Laemmli buffer. Proteins
were then resolved by SDS-PAGE and analyzed byWBwith bothmono-
clonal anti-MyBP-H and anti-ROCK2 antibodies.
2.4. Lambda phosphatase treatment
Lambda Protein Phosphatase (λ-PPase) (New England BioLabs)
treatment was performed as described in [16] with modiﬁcations. In
brief, muscle homogenates were resuspended in lysis buffer (1% w/v
NP-40, 1% w/v SDS, 50 mM Tris pH 7.6, 150 mM NaCl, protease inhibi-
tor cocktail); lysate (60 μg of protein) was brought to a ﬁnal volume
of 100 μl with distilled water and supplemented with 10 μl of 20 mM
MnCl2 solution and 10 μl of λ-PPase reaction buffer (New England
BioLabs). Each mixture was supplemented with λ-PPase (1000 units),
and incubated for 12 h at 30 °C. Proteins were acetone precipitated
(80% acetone ﬁnal concentration) at −20 °C for 12 h and used for
SDS-PAGE and WB analysis.
2.5. Immunoﬂuorescence
Skeletal muscle biopsies were frozen in cold 2-methylbutane and
then in liquid nitrogen and stored at−80 °C. Ten micrometer sections
were cut bymeans of a Leica cryostat and thenmounted on glassmicro-
scope slides. Sectionswere either used immediately or stored at−80 °C
prior to usage. Tissue sections were blocked for 2 h at 20 °C in PBS with
0.3% BSA, 0.3% Triton and 5% goat serum; theywere then incubatedwith
the primary antibody for 2 h at 20 °C or 12 h at 4 °C. Antibodies used
were: anti-MyBP-H, anti-fast myosin skeletal heavy chain and anti-
slow myosin skeletal heavy chain (Abcam). After washing with four
changes of blocking buffer without serum for a total of 1 h, the sections
were incubated with ﬂuorochrome-conjugated secondary antibody for
1 h at 20 °C (Invitrogen). The sections were ﬁnally washed for a total
of 1 h, mounted with Mowiol (Hoechst), and analyzed with OLYMPUS
BX51 ﬂuorescence microscope and a Leica DC 480 camera.
2.6. Statistical analysis
Gender distribution was analyzed by Fisher's exact test and two-
tailed p value. Continuous data were evaluated by unpaired Student's
t-test, if the data passed the normality test for Gaussian distribution as
assessed by the Kolmogorov–Smirnov test; alternatively, theywere eval-
uated by Mann–Whitney test. Two-tailed p value was used for the com-
parison of two means and standard error. Covariance was analyzed by
Kruskal–Wallis testwith Dunn'sMultiple Comparison post-test analyses.
In all analyses, p b 0.05 was considered to be statistically signiﬁcant. The
analysis was performed with Prism V4.03 software (GraphPad Inc.).3. Results
3.1. Protein differential expression in the muscle of ALS patients
Muscle biopsy protein extracts from CN (n = 10), ALS (n = 14) and
MN (n = 9) subjects were used to generate 2DE maps. Image analysis
showed 20 spots differentially expressed with statistical signiﬁcance
(ANOVA b0.05); for eleven of these spots, protein identiﬁcation was
assigned by MS analysis, which identiﬁed ten different proteins (Fig. 1)
(Supplemental materials SM—Table 1). The expression level of ﬁve pro-
teins (α-actin, actin prepeptide, myosin light chain 2, tropomyosin 3
isoform 1, β-tropomyosin) was lower in ALS than in CN, whereas the ex-
pression of one protein, MyBP-H, was higher in ALS than in CN. Compar-
ative analysis of ALS and MN revealed that the expression of 3 proteins
(MyBP-H, creatine kinase muscle, glyceraldehyde-3-phosphate dehy-
drogenase) was higher in ALS than in CN, and that the expression of 2
proteins (neuropolypeptide H3, β-myosin heavy chain) was lower in
ALS than in CN (SM—Table 1).
Validation of the observed protein expression changes performed by
WB analysis with speciﬁc antibodies failed to conﬁrm statistical signiﬁ-
cance for 9 out of 10 proteins (not shown). This was probably due to the
fact that most of the differentially expressed spots proved to be protein
fragments. In contrast, WB validation experiments conﬁrmed signiﬁ-
cant expression changes for MyBP-H [17]; we accordingly focused our
attention on this protein.3.2. Increased expression of Myosin binding protein H in ALS patients
Western blot analysis showed that the expression level of MyBP-H
was able to discriminate between varying populations as inferred by
Kruskal–Wallis test (p b 0.0001). MyBP-H expression was higher in
ALS than in CN and/or MN patients, and the differences, as evaluated
with Dunn's Multiple Comparison post-test analysis (respectively
p b 0.001 and p b 0.01) (Fig. 2A and B), proved to be signiﬁcant.
MyBP-H expression in CN and MN was generally weak, and for some
samples, undetectable (Fig. 2A). MyBP-H expression was not related
to the origin of muscle specimen, namely, vastus versus gracilis, since
the molecule was highly expressed in ALS patients and weakly or not-
expressed in CN and MN, regardless of the type of muscles. However,
three MN patients (MN6, MN8 and MN9) showed MyBP-H expression
levels that were comparable to those of ALS patients with lower
MyBP-H expression (Fig. 2B). We accordingly investigated a further
control group of patients in whom muscular damage was not related
to neuronal diseases (chronic and acute myopathies). MyBP-H expres-
sion proved to be higher in the myopathy (M) cohort than in controls,
albeit to a lesser extent than in ALS patients (Fig. 2A and B). These
results likewise indicate that MyBP-H expression was not related to a
speciﬁc muscle source, as both CN and M specimens derived mainly
from the vastus muscle. However, the size of the myopathy cohort
was insufﬁcient for the MyBP-H increase in question to be granted sta-
tistical signiﬁcance. Given the higher degree of muscular damage in
myopathic as compared to ALS samples, the relatively lower increase
in MyBP-H suggests that its expression does not merely correlate with
muscular damage. That the expression ofMyBP-H in the skeletalmuscle
of ALS patients differed from that in control groups was conﬁrmed by
immunoﬂuorescence onmuscle cryo-sections from the same specimens
as those used for 2DE analysis. In agreement with the results obtained
byWB analysis, staining for MyBP-Hwas positive in ALS and in myopa-
thy samples, but was negative or very weakly positive in CN and MN
samples (Fig. 2C).
We then applied 2DE andWB to investigate whetherMyBP-H in ALS
patients had undergone biochemical changes as a result of post-
translational modiﬁcations. Results showed no variations between the
electrophoretic mobility patterns respectively found in ALS, CN and
MN subjects (SM—Fig. 1).
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Fig. 1. Protein differential expression in ALS patients muscle. A) Two-dimensional electrophoresis map of muscle homogenate from a representative ALS patient. Proteins were separated
by pI in the ﬁrst dimension on a pH 3–10 NL, and bymolecular weight in the second dimension on a 9–16% acrylamide gradient SDS-PAGE. Protein spots were revealed by silver staining.
The protein spots that follow image analysis showed differential expression among patients and controls are indicated by arrows. Spot numbers are referred tomass spectrometry protein
identiﬁcation reported in Supplemental materials Table 1. B) Comparisons of protein spots expression in control healthy subjects (CN) and ALS patients. Enlargements of the 2DE areas of
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myosin binding proteins, namely MyBP-C and MyBP-H [18,19]. These
proteins, which differ in terms of the N-terminal domains, are both
associated, via the C-terminal domain, with myosin in the A-band of
the thick ﬁlaments in myoﬁbrils [18]. We accordingly investigated
whether MyBP-C expression too was affected in ALS muscles. WB anal-
ysis revealed no changes in expression (SM—Fig. 2).A 
B 
anti-MyBP-H 
CN4 ALS5 ALS7ALS6 CN5 CN6
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Fig. 2.Myosin binding protein H increased expression in ALS patients. A)Western Blot analysis
patients (sALS, n = 17), healthy subjects (CN, n = 11), motor neuropathies patients (MN, n =
reported as patient vs. control rate. Data were analyzed by covariance analysis performed wit
groupswith the Dunn'sMultiple Comparison Test (**, p b 0.01; ***, p b 0.001). C) Immunoﬂuor
tative highly expressing MyBP-H ALS patients (ALS5 and 6, upper and lower, respectively), hea3.3. Increased expression of MyBP-H in ALS is not associated with fast
twitch muscle ﬁber enrichment
In chicken and rabbit skeletalmuscles, MyBP-H has been reported to
be primarily associatedwith fast twitchmuscle ﬁbers [20,21]. As we an-
alyzed all themuscle samples collected at disease onset, we investigated
whether the anomalous expression ofMyBP-H in damaged ALSmusclesC anti mouse Ig 
ALS 
CN 
MyBP-H 
MN 
ALS 
M 
performedwith anti-MyBP-H antibody on skeletal muscle homogenate from sporadic ALS
9) and myopathies patients (M, n = 6). B) Analysis of WB signal optical density (O.D.)
h the Kruskal–Wallis test (****KW, p b 0.0001) and post-analysis test between individual
escence staining ofMyBP-H on transverse sections of skeletal muscle biopsies of represen-
lthy subject (CN5), motor neuropathy (MN3) and myopathy (M2).
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these latter co-occurred with an unsuccessful attempt at muscular re-
generation. The transition of muscle ﬁber phenotype from slow to fast
can indeed be induced by denervation/re-innervation neuromuscular
activity [23]. Immunoﬂuorescence against slow- and fast-myosin ﬁbers
performed on ALS patients, healthy subjects (CN) and MN patients
showed comparable percentages of fast-myosinﬁbers in the three groups,
which suggests that MyBP-H expression was not associated with fast
twitch muscle ﬁber enrichment in ALS patients (Fig. 3A and B). Muscular
regeneration is associated with the transitional expression of neonatal
myosin before the switch to adult isoforms that takes place under the
control of reconstituted nerve activity [22].Western blot analysis showed
no signiﬁcant differences in the respective expression levels of neonatal
myosin in ALS, CN and MN (SM—Fig. 3).
3.4. ROCK2, LIMK1 and coﬁlin2 levels increase in ALS samples
In lung adenocarcinoma cell lines,MyBP-H has been reported to be a
transcriptional target of TTF-1 and to physically interactwith Rho kinase
1 (ROCK1); this interaction inhibits MyBP-H activity, which in turn
affects actin–myosin interaction and cell motility [24]. We accordingly
investigatedwhetherMyBP-H expression in ALS skeletalmuscle is asso-
ciated with increased expression of TTF-1, and whether MyBP-H func-
tionally interacted with ROCK kinases. Western blot analysis showed
the level of TTF-1 expression in ALS muscles to be low and comparable
to that observed in CN (data not shown). Interestingly, ROCK2, the
ROCK isoform expressed in muscle [25,26], was signiﬁcantly higher in
ALS than in CN samples (p = 0.0298 by Mann–Whitney test) (Fig. 4A).CN
(n= 10)
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(n= 14)
MN
(n= 9)
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Fig. 3. Presence of slow- and fast-myosin ﬁbers. A) Immunoﬂuorescence staining of slow-
and fast-myosinﬁbers performedon transverse sections of skeletalmuscle biopsies of rep-
resentative CN, sALS andMN. B)Analysis of the percentage of fast-myosinﬁbers present in
three different ﬁelds of immunostaining performed on transverse sections of healthy sub-
jects (CN, n = 10), sporadic ALS patients (ALS, n = 14), andmotor neuropathies patients
(MN, n = 9). No statistical differences occurred as inferred by covariance analysis per-
formed with the Kruskal–Wallis test and Dunn's post-analysis test.We therefore investigated whether ROCK2 interacted with MyBP-H
in ALS samples. Co-immunoprecipitation experiments performed re-
spectively with monoclonal and polyclonal anti-MyBP-H antibodies
followed by WB with anti-ROCK2 revealed no physical interaction
between the two molecules (SM—Fig. 4).
Given the functional role that ROCK2 plays in actin–myosin interac-
tion and function, the increased expression in ALSprompted us to inves-
tigate the downstream targets of its kinase activity. The ROCK pathway
leads to actin–myosin ﬁlament assembly, in which contractile force is
generated by the phosphorylation of numerous substrate proteins
[27]. ROCKs exert their kinase activity through two differing target
pathways: 1) phosphorylation of LIM kinases, whose speciﬁc activity
on coﬁlin increases and causes inactivation of coﬁlin's actin depolymer-
ization function; this in turn results in actin ﬁlament stabilization;
2) phosphorylation of the regulatory myosin light chain (M-RLC), and
phosphorylation of the myosin-binding subunit 1 (MYPT1), which
inhibits myosin phosphatases; this in turn results in myosin binding to
the actin ﬁlament and hence to the initiation of contraction [27].
Interestingly, WB analysis revealed higher expression of both
LIMK1 and coﬁlin2 in ALS than in CN muscle samples (p = 0.0004 by
Mann–Whitney test and p = 0.0065 by Student's t test, respectively)
(Fig. 4B and C). In contrast, no changes in the expression levels were de-
tected in ALS samples for proteins belonging to theM-RLC downstream
pathway (data not shown).
3.5. A non-phosphorylated LIMK1 isoform accumulates in ALS muscles
As evidenced in Fig. 4B, LIMK1 in ALS patients showed two bands of
similar intensity, while in CN the upper band markedly prevailed over
the non-detectable or very faint lower band. Optical density analysis
showed that the expression level of the upper band was similar in
both CN and ALS samples (p = 0.1388 by Mann–Whitney), whereas
the lower band was responsible for the relative increase observed in
ALS samples (p = 0.0018 by Mann–Whitney test) (Fig. 5A). Treatment
with lambda phosphatase (λ-PPase) induced the appearance of a lower
band in CN and an accumulation of the signal in the lower band in ALS
patients. This ﬁnding indicates that the upper band is the phosphorylat-
ed isoform of LIMK1, which prevails in healthy subjects, and that a non-
phosphorylated isoform of LIMK1 had accumulated in ALS patients
(Fig. 5B). Use of WB with speciﬁc antibodies did not enable us to detect
coﬁlin2 phosphorylation in the samples (data not shown); however,
2DE and WB analysis indirectly suggested that, downstream to LIMK1,
coﬁlin2 was less phosphorylated in ALS patients than in CN subjects.
This feature was evidenced by the fact that spot acidity was lower in
ALS than in CN samples (Fig. 6). In contrast, the same analysis suggested
that phosphorylation of the ROCK downstream-target MLC2 protein in
ALS samples does not differ from that in ALS compared to CN samples,
since the MLC2 isoelectric points were identical in the two groups
(SM—Fig. 5).
These results show that the increased expression of MyBP-H in ALS
samples is associated with abnormal expression of ROCK2 and the
downstream targets LIMK1 and coﬁlin2.
4. Discussion
To date, muscle has played a limited role in the identiﬁcation of bio-
markers in ALS, even though the demonstration of muscular abnormal-
ities made such a role conceivable [28,29]. Of particular pertinence in
this respect are the reports showing that motor neuron degeneration
might occur in a retrograde fashion as a consequence of the early desta-
bilization of the neuro-muscular junction (NMJ) ([29] and references
therein) [5,6].
The main ﬁnding of this work is that, at disease onset, the skeletal
muscles of ALS patients show increased expression of a putativemarker,
namelyMyBP-H, that is already able at onset to distinguish ALS patients
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Fig. 4.Western blot analysis of ROCK2, LIMK1 and coﬁlin2 expression. Analysis was performed on skeletal muscle homogenate from sporadic ALS patients (ALS) and healthy subjects
(CN). Analysis of WB signal optical density (O.D.) obtained with antibodies speciﬁc for ROCK2 (A), LIMK1 (B) and coﬁlin2 (C) is reported as patient vs. control rate. Data were analyzed
by Mann–Whitney test (A, p = 0.0298; B, p = 0.0004) and by Student's t test (C, p = 0.0065).
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other similarly incipient motor neuropathies.
MyBP-H is a myoﬁbrillar protein constituent of vertebrate skeletal
muscle of about 55 kDa. Located in the A-band of the myoﬁbrils, it is
closely associated with the thick ﬁlaments, but its primary association
is with the ﬁbers of fast twitch muscles [18–21]. A functional role for
MyBP-H has not yet been described. A further associate of the thick ﬁl-
ament of myosin is MyBP-C, another member of the family of myosin
binding proteins [18,19]; this member of the family shares MyBP-H's
signiﬁcant homology at the carboxyl-terminal domains, the region in-
volved in myosin binding. Unlike MyBP-C, MyBP-H lacks the amino-
terminal region, which is responsible for the regulation of myosin
contractile functions [18,19,30]. The demonstration that the myosin
binding domain of MyBP-C can replace that of MyBP-H without affect-
ing its localizationmakes it conceivable that MyBP-H partially compen-
sates for the lack ofMyBP-C [18]. However, the observation thatMyBP-C
expression was similar in ALS, MN and CN groups rules out thisCN  
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Fig. 5. Non-phosphorylated isoform of LIMK1 is accumulated in ALS patients. A) Analysis
of WB signal optical density (O.D.) of upper and lower bands revealed with anti-LIMK1
in healthy subjects (CN) and sporadic ALS (sALS) (see Fig. 4B). Data, reported as patient
vs. control rate, were analyzed by Mann–Whitney test (**p = 0.0018). B) WB analysis
of LIMK1 dephosphorylation in CN and sALS muscle homogenate following λ-
phosphatase (λ-PPase) treatment. Lower band signal appearance in CN and accumulation
of the signal in the lower band in ALS as consequence of λ-PPase treatment indicated that
the upper band is the phosphorylated isoform of LIMK1 that is prevalent in CN.hypothesis. The possibility that MyBP-H expression was related to the
degree of muscular damage was also excluded on the grounds that the
myopathic samples, in which muscular damage was higher than in
ALS samples, showed an increase in MyBP-H compared to CN that was
lower than that found in ALS patients. This observation suggests that
the over-expression of MyBP-H might not depend, or might only par-
tially depend, on muscular damage.
The reported association of MyBP-H with fast twitch ﬁbers in skele-
tal muscle of chicken and rabbit [20,21] led us to hypothesize that its
over-expression in sALS could be related to an attempt at regeneration
that the muscle made in the early phase of the disease (i.e., when NMJ
alteration occurred). The presence of fast twitch muscle ﬁbers and neo-
natal myosin have been associated with denervated-regeneratingmus-
cle [22], and single muscle ﬁber contractile analysis has demonstrated
that fast-twitch muscle ﬁbers and neuromuscular junctions are prefer-
entially affected by ALS-induced denervation [31]. Although the expres-
sion in ALS muscles both of fast myosin and of neonatal myosin didPonceau 
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Fig. 6. A Less acidic isoform of coﬁlin2 is expressed in ALS patients. 2DE analysis and WB
performed with anti-coﬁlin2 on muscle homogenate of a representative healthy subject
(CN) and sporadic ALS patients respectively. Electrophoretic mobility feature of coﬁlin2
spots, indicated by the black arrows on the Ponceau red stained membranes, and the sig-
nals revealed by the anti-coﬁlin2 (black arrows onWB) showed a less acidic coﬁlin2 inALS
patients compared to healthy subjects, which in turnmay suggest a reduced/absent phos-
phorylation in ALS patients. The white head-arrows indicated the non-speciﬁc signal vis-
ible in the WB that has been used for image alignment.
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vations suggest that changes in MyBP-H expression precede changes in
the myosin chain composition consequences of denervation.
The observations we made in ALS patients are supported both at
mRNA and protein levels in ALS animal models. An increase in MyBP-H
expression at the transcriptional level has been reported in the muscle
of SOD1G86R transgenic mice ALS model [32]. The increase was observed
in the early stage of disease onset, when the ﬁrst signs of peripheral de-
nervation and muscular atrophy are not caused by degeneration of the
motor neuron, but are rather the result of axonal dysfunction [32]. A
similar conclusion was inferred by the observation of the induction of
MyBP-H mRNA expression in mice 7 days after sciatic nerve axotomy,
prior to motor neuron death [32]. In these animal models, the induction
of genes implicated in myogenesis and cytoskeleton organization has
been proposed as playing an important role in stimulating the regenera-
tive capacity of muscle during the ﬁrst steps of atrophy [32]. At a protein
level, an increase inMyBP-H expression has been reported in themuscle
of 7-week-old SOD1G93A transgenic mice models for ALS, when overt
clinical symptoms at hindlimbs, like weakness and tremor, have yet to
occur [33]. Interestingly, decreased MyBP-H expression in 14-week-old
SOD1G93A mice occurred exclusively in the gastrocnemius muscle of
pathologically compromised hindlimbs, but not in the triceps muscle of
the then not compromised forelimbs [33]. Furthermore, increased
mRNAexpression ofMyBP-Hwas reported in allmuscles of rats pharma-
cologically paralyzed by post-synaptic block of neuromuscular transmis-
sion (NMB) [34]. In response to NMB, MyBP-H showed a transcriptional
regulation that differed completely from that of all other myoﬁbrillar
proteins, which are down-regulated. This ﬁnding suggests that MyBP-H
up-regulation might represent an early sign of muscle regeneration
[34]. Interestingly, the ALS samples submitted to proteomics analysis
revealed a similar behavior: while several myoﬁbrillar proteins were
down-regulated, MyBP-H expression exclusively increased. It is note-
worthy that, during themuscular wasting/atrophy that occurs in the ab-
sence of NMJ alteration, as in response to food deprivation, MyBP-H
expression was reported as having decreased [35,36]. The results of our
study are consistent with a model whereby muscular alteration is an
early pathological event in ALS [5,6,8]; whether this event is associated
with NMJ alteration and is independent from motor neuron degenera-
tion remains to be deﬁned.
From the molecular point of view, MyBP-H negatively regulates
actomyosin organization in non-muscle cells, and thus inhibits both
the phosphorylation of myosin regulatory light chain (M-RLC) and the
assembly of non-muscle myosin heavy chain IIA (NMHC IIA) [24,37].
The inhibitory function is exerted by an interaction with both NMHC
IIA and ROCK1, the latter being the kinase responsible for M-RLC phos-
phorylation [24,37]. ROCK1 and ROCK2 are key regulators of cellular ac-
tomyosin contractility by means of the phosphorylation of substrates,
which included LIMK kinases and M-RLC2 [38,39]. In non-muscle cell,
the ROCK1 negative regulatory function exerted by MyBP-H resulted
in a lack of LIMK phosphorylation/activation, which in turn promoted
the activation of the actin-depolymerizing factor coﬁlin [24]. Our ﬁnd-
ings show that increased expression of MyBP-H co-occurs with altered
expression of ROCK2, as well as with altered expression/phosphoryla-
tion of LIMK1 and coﬁlin2; these ﬁndings might suggest that, analo-
gously with non-muscle cells, skeletal muscle might be characterized
by a functional relation between these actomyosin regulators. However,
without evidence of reduced ROCK2 kinase activity, it cannot be exclud-
ed that the observed alteration in LIMK1phosphorylation derives froma
different signaling pathway, since LIMK1 is the target of several kinases.
Furthermore, the lack of molecular interaction between MyBP-H and
ROCK2 prevents us from concluding whether increased expression of
MyBP-H affects ROCK2 kinase activity andwhether it is directly respon-
sible for the molecular changes observed. Indeed, we cannot exclude
that MyBP-H over-expression exerts its function through a completely
different mechanism whereby myosin binding properties of MyBP-H
attempt to stabilize myosin ﬁlaments.5. Conclusions
The increased expression ofMyBP-H in the skeletalmuscle of ALS pa-
tientsmight possibly be amarker for the purposes of differential diagno-
sis, in that the increase may reﬂect muscular alteration and, possibly, an
attempt at regeneration. To understand why the compensatory mecha-
nism failswill be the next step in research. The generation of a transgenic
animal model would help research to establish whether MyBP-H plays a
directly detrimental or proactive role in these mechanisms.
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